Table 3.
ITGB3 Leu33Pro (T>C, rs5918) genotype frequencies by disease status and ovarian cancer hazard ratio estimates for BRCA1 mutation carriers by mutation class
| Gene | Genotype | Unaffected (%) | Affecteda (%) | HR | 95% CI | P-value |
|---|---|---|---|---|---|---|
| Breast cancer analysis | ||||||
| BRCA1-Class1 | TT | 2444 (72.8) | 2450 (72.9) | 1.00 | ||
| TC | 840 (25.0) | 835 (24.9) | 1.01 | 0.91–1.12 | ||
| CC | 73 (2.2) | 74 (2.9) | 1.06 | 0.77–1.46 | ||
| 2df test | 0.92 | |||||
| Per-allele | 1.02 | 0.93–1.11 | 0.72 | |||
| BRCA1-Class2 | TT | 908 (75.4) | 1086 (73.7) | 1.00 | ||
| TC | 273 (22.7) | 363 (24.6) | 1.05 | 0.89–1.24 | ||
| CC | 23 (1.9) | 25 (1.7) | 0.90 | 0.52–1.55 | ||
| 2df test | 0.76 | |||||
| Per-allele | 1.02 | 0.89–1.18 | 0.75 | |||
| Ovarian cancer analysis | ||||||
| BRCA1-Class1 | TT | 4029 (73.2) | 865 (71.2) | 1.00 | ||
| TC | 1357 (24.7) | 318 (26.2) | 1.08 | 0.93–1.25 | ||
| CC | 116 (2.1) | 31 (2.6) | 1.16 | 0.79–1.72 | ||
| 2df test | 0.49 | |||||
| Per-allele | 1.08 | 0.95–1.22 | 0.23 | |||
| BRCA1-Class2 | TT | 1701 (75.2) | 293 (70.6) | 1.00 | ||
| TC | 525 (23.2) | 111 (26.8) | 1.22 | 0.94–1.57 | ||
| CC | 37 (1.6) | 11 (2.6) | 1.62 | 0.89–2.95 | ||
| 2df test | 0.12 | |||||
| Per-allele | 1.24 | 1.00–1.53 | 0.048 | |||
| Excluding IHCC: | ||||||
| Per-allele | 1.01 | 0.78–1.32 | 0.92 | |||
a
Diagnosed with breast or ovarian cancer according to analysis